• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Partnership aims to develop equine embryonic stem-cell lines for lameness therapies

November 28, 2008

Austin, Texas -- Creating a bank of stem cells genetically matched to individual horses is the goal of a newly announced partnership between Austin-based Viagen Inc. and the Monash Institute of Melbourne, Australia.

Austin, Texas

-- Creating a bank of stem cells genetically matched to individual horses is the goal of a newly announced partnership between Austin-based Viagen Inc., an animal genetics company, and the Monash Institute of Melbourne, Australia.

The performance-horse industry could be among the first to benefit from the harnessing of embryonic stem cells to repair tendon, ligament, cartilage and bone damage, the partners say, though they expect the work to have far wider applications.

Dr. Paul Verma of the Monash Institute of Medical Research is working to develop the embryonic stem-cell lines to create a bank of them matched to specific horses.

The cells have the potential to reverse tendon, ligament, cartilage and bone damage that can end a horse's athletic career, and in some cases even result in euthanasia, the partners say.

"We have developed techniques to derive stem cells from horse embryos, and through a pilot study we have successfully created a number of equine embryonic stem-cell lines," Verma says. "The next step will be to look at using these lines to regenerate (damaged) cells. Once the stem cells can be coaxed into 'becoming' the appropriate tissue cells, they can be transplanted to replace the original cells."

Advertisement

Because the therapeutic cells will be recognized by a horse's immune system as its own, there will be no risk of tissue rejection, according to a news release from ViaGen.

"The risk of rejection will be overcome because the new tissue will genetically match the horse receiving treatment," explains Dr. Irina Polejaeva, chief scientific officer for ViaGen, which bills itself as "The Cloning Company."

Current stem-cell therapies involve aspirating adipose (fat) cells or bone-marrow cells from the injured horse, which are sent to a laboratory and grown into the required tissue cells over a period of up to three weeks.

Three advantages embryonic cells have over the current system, ViaGen says, are flexibility to make any cell type, the fact that one embryonic cell can potentially provide an endless supply of cells with defined characteristics and unlimited production of embryos through somatic cell nuclear transfer process.

Related Content:

Equine MedicineBreaking NewsEquine
Texas Tech professor inspires students with large animal surgery
Texas Tech professor inspires students with large animal surgery
SoCal Equine Hospital installs innovative CT scanner
SoCal Equine Hospital installs innovative CT scanner
Morris Animal Foundation announces study looking at coping strategies in horses
Morris Animal Foundation announces study looking at coping strategies in horses

Advertisement

Latest News

3 Must-sees for Women's History Month

News wrap-up: This week’s headlines, plus Embrace announces its top Irish pet names

Oldest tortoise at Houston Zoo becomes father to 3 hatchlings

Veterinary tech students awarded national scholarship

View More Latest News
Advertisement